Biomarkers
Test 163. Carrier Analysis of Variants Associated with Reproductive Disadvantages
Test 165. BRCA-свързан разширен панел за оценка на фамилен риск и избор на терапия
Test 166. Избор на терапия при карцином на гърда
Test 167. Избор на терапия при карцином на гърда
Test 168. Избор на терапия при карцином на простатата
Test 169. Избор на терапия при солидни тумори, свързани с дефицит на хомоложна рекомбинация (рак на гърдата, яйчник, простата и панкреас)
Test 170. Геномно профилиране във връзка с избор на терапия при солидни тумори
Test 171. Таргетно секвениране на панел от гени при солидни тумори във връзка с избор на терапия
Test 172. Prognostic markers in tumors of the central nervous system
Test 173. Prognostic markers in tumors of the central nervous system
Test 174. Prognostic markers in tumors of the central nervous system
Test 175. Diagnostic markers for tumors in the central nervous system, endometrium, stomach, and others
Test 176. Diagnostic markers for tumors in the central nervous system, endometrium, stomach, and others
Test 177. Diagnostic and prognostic markers in brain, PNET, thyroid and other tumors
Test 178. Diagnostic and prognostic markers in brain, PNET, thyroid and other tumors
Test 179. Diagnostic and prognostic markers in brain, PNET, thyroid and other tumors
Test 180. Diagnostic marker for the presence of DICER1 syndrome
Test 181. Diagnostic and Predictive Markers for Targeted Therapy in Gastrointestinal Stromal Tumor (GIST)
Test 182. Diagnostic and Predictive Markers for Targeted Therapy in Gastrointestinal Stromal Tumor (GIST)
Test 183. Diagnostic and Predictive Markers for Targeted Therapy in Gastrointestinal Stromal Tumor (GIST)
Test 184. Diagnostic and Predictive Markers for Targeted Therapy in Gastrointestinal Stromal Tumor (GIST)
Test 185. Predictive marker BRAF (V600) mutations for targeted therapy in oncological diseases (melanoma, colorectal and lung carcinomas, thyroid gland, GIST, brain tumors, etc.)
Test 186. Predictive marker for targeted therapy in chronic lymphocytic leukemia (CLL)
Test 187. Предиктивен маркер за таргетна терапия при хронична лимфоцитна левкемия/ХЛЛ/
Test 188. Predictive marker for targeted therapy in chronic lymphocytic leukemia (CLL)
Test 189. Optimizing therapy with the indirect anticoagulant acenocoumarol (Syntrom)
Test 190. Optimizing therapy with the antiplatelet agent clopidogrel (Plavix)
Test 191. Optimization of methotrexate therapy
Test 192. Optimizing Isoniazid for the treatment of pulmonary tuberculosis
Test 193. Investigation of DPYD variants to optimize chemotherapy with 5-fluorouracil and capecitabine
Test 194. Изследване на UGT1A1 вариант за оптимизиране на химиотерапията
Test 195. Minimal residual disease in patients with neuroblastoma
Test 196. Optimizing therapy with drugs from the thiopurine group (Azathioprine, Mercaptopurine and Thioguanine)
Test 197. Optimizing therapy with drugs from the thiopurine group (Azathioprine, Mercaptopurine and Thioguanine)
Test 198. Slow metabolizers by CYP2C9
Test 199. Slow metabolizers by CYP2C19
Test 200. Slow metabolizers by CYP2D6
Test 201. Diagnostic markers in brain, rhabdoid, solid and other tumors
Test 202. Diagnostic markers in brain, rhabdoid, solid and other tumors
Categories
Inherited Oncological Diseases
Rare Diseases
Clinical Exome
Prenatal Diagnostics
Neurological and Neurodegenerative Diseases
Ocular and Ear Diseases
Kidney and Cardiovascular Diseases
Biomarkers
Congenital Аnomalies
Mitochondrial and Metabolic Diseases
Connective Tissue Diseases
Endocrinological Diseases